Literature DB >> 33501511

Can the mesorectal fat tissue volume be used as a predictive factor in foreseeing the response to neoadjuvant chemoradiotherapy in rectum cancer? A CT-based preliminary study.

Okan Dilek1, Huseyin Akkaya2, Cenk Parlatan2, Tolga Koseci3, Zeynel Abidin Tas4, Gökhan Soker2, Bozkurt Gulek2.   

Abstract

PURPOSE: This study was to investigate the effect of mesorectal fat tissue volume (MRV) on the pathological response to neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer.
METHODS: 88 patients who had been diagnosed with locally advanced rectal cancer between January 2017 and June 2020 were reviewed retrospectively. The total abdominal, subcutaneous, visceral, and mesorectal fatty tissue components were measured semiquantitatively by two radiologists using computed tomography (CT)-based findings. The patients were divided into two groups as those with and without a pathological response to nCRT. The relationship of MRV with the other fat tissue components of the body was also evaluated.
RESULTS: We performed a retrospective analysis of 88 patients (mean age 62.7 years [range, 33-90 years]; 31 males and 57 females). A positive response to nCRT was present in 47 patients. There were 59 patients with stage 3 disease. 46 patients demonstrated lymph node involvement. The mean MRV was 69.6 ± 31.0 ml in no-response group and 105.8 ± 47.5 ml in response-positive patients (p < 0.05). MRV showed the highest correlation with visceral fat volume (VFV). There was a negative correlation between the MRV and the N stage. A cut-off value of ≥ 69.4 for MRV predicted the repsonse to nCRT, with 82.9% sensitivity and 58.5% specificity [AUC: 0.757 (0.653-0.842), p < 0.001] in receiver operating characteristic (ROC) curve analysis
CONCLUSIONS: MRV can be used as a novel parameter in predicting of pathological response to nCRT in locally advanced rectal cancer patients.

Entities:  

Keywords:  Mesorectal fat tissue volume; Neoadjuvant chemoradiotherapy; Pathological response; Rectum cancer

Mesh:

Year:  2021        PMID: 33501511     DOI: 10.1007/s00261-021-02951-x

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  6 in total

1.  Morphology of the mesorectum in patients with primary rectal cancer.

Authors:  Kirsten M Boyle; Alan G Chalmers; Paul J Finan; Peter M Sagar; Dermot Burke
Journal:  Dis Colon Rectum       Date:  2009-06       Impact factor: 4.585

2.  Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation.

Authors:  Whalen Clark; Erin M Siegel; Y Ann Chen; Xiuhua Zhao; Colin M Parsons; Jonathan M Hernandez; Jill Weber; Shalini Thareja; Junsung Choi; David Shibata
Journal:  J Am Coll Surg       Date:  2013-03-21       Impact factor: 6.113

3.  The Swedish rectal cancer registry.

Authors:  L Påhlman; M Bohe; B Cedermark; M Dahlberg; G Lindmark; R Sjödahl; B Ojerskog; L Damber; R Johansson
Journal:  Br J Surg       Date:  2007-10       Impact factor: 6.939

Review 4.  Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.

Authors:  J E Ryan; S K Warrier; A C Lynch; A G Heriot
Journal:  Colorectal Dis       Date:  2015-10       Impact factor: 3.788

5.  Global patterns and trends in colorectal cancer incidence and mortality.

Authors:  Melina Arnold; Mónica S Sierra; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

6.  Higher visceral fat area/subcutaneous fat area ratio measured by computed tomography is associated with recurrence and poor survival in patients with mid and low rectal cancers.

Authors:  Kang Hong Lee; Bo-Kyeong Kang; Byung Kyu Ahn
Journal:  Int J Colorectal Dis       Date:  2018-04-30       Impact factor: 2.571

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.